Asset Details
Do you wish to reserve the book?
Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension
Do you wish to request the book?
Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension
2013
Overview
In an event-driven trial, macitentan (an endothelin-receptor antagonist) at a dose of 3 or 10 mg was compared with placebo in patients with symptomatic pulmonary arterial hypertension. At a median of 115 weeks, both macitentan doses were associated with reduced morbidity and mortality.
Pulmonary arterial hypertension, a severe disease characterized by a sustained elevation of pulmonary vascular resistance, ultimately leads to right heart failure and death.
1
Disease progression occurs despite the availability of drugs that are specific for the disorder.
2
Endothelin-receptor antagonists, phosphodiesterase type 5 inhibitors, and prostacyclin and its analogues have been approved for the treatment of pulmonary arterial hypertension and adopted clinically on the basis of short-term trials (12 to 16 weeks) that have shown improvements in exercise capacity as measured by the distance walked in 6 minutes.
3
–
10
However, current guidelines suggest that the primary end point in phase 3 . . .
Publisher
Massachusetts Medical Society
Subject
/ Biological and medical sciences
/ Endothelin A Receptor Antagonists
/ Endothelin B Receptor Antagonists
/ Familial Primary Pulmonary Hypertension
/ Female
/ Headache
/ Hospitalization - statistics & numerical data
/ Humans
/ Hypertension, Pulmonary - complications
/ Hypertension, Pulmonary - drug therapy
/ Hypertension, Pulmonary - mortality
/ Male
/ Patients
/ Public health. Hygiene-occupational medicine
/ Pulmonary hypertension. Acute cor pulmonale. Pulmonary embolism. Pulmonary vascular diseases
/ Pyrimidines - adverse effects
/ Pyrimidines - therapeutic use
